RT Journal Article
SR Electronic
T1 Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.23.22272828
DO 10.1101/2022.03.23.22272828
A1 Rice, Christopher M.
A1 Lewis, Philip
A1 Ponce-Garcia, Fernando M.
A1 Gibbs, Willem
A1 Cela, Drinalda
A1 Hamilton, Fergus
A1 Arnold, David
A1 Hyams, Catherine
A1 Oliver, Elizabeth
A1 Barr, Rachael
A1 Goenka, Anu
A1 Davidson, Andrew
A1 Wooldridge, Linda
A1 Finn, Adam
A1 Rivino, Laura
A1 Amulic, Borko
YR 2022
UL http://medrxiv.org/content/early/2022/04/26/2022.03.23.22272828.abstract
AB Neutrophils are vital in defence against pathogens but excessive neutrophil activity can lead to tissue damage and promote acute respiratory distress syndrome (ARDS). COVID-19 is associated with systemic expansion of immature neutrophils but the functional consequences of this shift to immaturity are not understood. We used flow cytometry to investigate activity and phenotypic diversity of circulating neutrophils in acute and convalescent COVID-19 patients. First, we demonstrate hyperactivation of immature CD10− subpopulations in severe disease, with elevated markers of secondary granule release. Partially activated immature neutrophils were detectable three months post symptom onset, indication long term myeloid dysregulation in convalescent COVID-19 patients. Second, we demonstrate that neutrophils from moderately ill patients downregulate the chemokine receptor CXCR2, while neutrophils from severely ill individuals failed to do so, suggesting altered ability for organ trafficking and a potential mechanism for induction of disease tolerance. CD10−and CXCR2hi neutrophil subpopulations were enriched in severe disease and may represent prognostic biomarkers for identification of individuals at high risk of progressing to severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Medical Research Council (MRC) and Elizabeth Blackwell Institute for Health Research, University of Bristol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics committee of the National health service (NHS) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors